Analysis of data from the DOMINO-AD Trial indicates that the drug Donepezil may be effective in avoiding care home admissions in more advanced cases of Alzheimer’s Disease. Discontinuation of donepezil appears to be associated with an increased risk of nursing home admissions in community-living patients with moderate-to-severe Alzheimer’s Disease during the first 12 months following drug cessation.
Full reference: Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology. [Epub ahead of print].
Related: Dementia drug ‘keeps patients out of nursing homes’ BBC News